NASDAQ · VERA
Vera Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VERA: Nov 05, 2026
Vera Therapeutics, Inc. Class A Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.72. The reported EPS for the same quarter last year was $-1.26.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.72 | $-1.60 | $-1.81 | 6 |
| Dec 2026 | $-1.51 | $-1.33 | $-1.66 | 5 |
| Mar 2027 | $-1.35 | $-1.19 | $-1.51 | 4 |
| Jun 2027 | $-1.21 | $-1.12 | $-1.35 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Fintel · Zacks- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- MarketBeat · Oct 22, 9:04 PM EDTVera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results3 Biotech Firms With Major Potential Catalysts in the Coming MonthsVera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the Ame
- RTTNews · Oct 22, 10:59 AM EDTVera's TRUTAKNA Shows Kidney Benefit In Final Phase 3 IgA Nephropathy Analysis(RTTNews) – Vera Therapeutics, Inc. (VERA) announced positive final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in adults with primary IgA nephropathy (IgAN), with the data presented at ASN Kidney Week 2026 and reported in the New England Journal
- Fintel · Oct 12, 8:47 PM EDTLeerink Partners Initiates Coverage of Vera Therapeutics at Market PerformFintel reports that on October 12, 2026, Leerink Partners initiated coverage of Vera Therapeutics (NASDAQGM:VERA) with a Market Perform recommendation. The initiation of coverage occurred on a day when the stock's latest close was recorded at $27.75 on October 12, 2026. This foll
- Zacks · Sep 24, 10:27 AM EDTWill Vertex's Kidney Disease Pipeline Be a New Growth Engine?VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
- RTTNews · Sep 18, 10:44 AM EDTWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) – Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
- BNK Invest · Sep 15, 3:18 PM EDTNoteworthy Tuesday Option Activity: AVGO, VERA, QCOMAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Broadcom Inc (Symbol: AVGO), where a total of 251,524 contracts have traded so far, representing approximately 25.2 million underlying shares. That amounts to about 97.1
- RTTNews · Sep 15, 7:36 AM EDTVera's TRUTAKNA Shows Two-Year Kidney Protection; SBLA Planned Q4 2026; Stock Up(RTTNews) – Vera Therapeutics, Inc. (VERA) reported that its therapy TRUTAKNA stabilized kidney function and prevented disease progression in adults with primary IgA nephropathy over two years in the pivotal ORIGIN 3 trial.
- BNK Invest · Aug 25, 4:04 PM EDTNoteworthy Tuesday Option Activity: VERA, DHT, PLABAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vera Therapeutics Inc (Symbol: VERA), where a total of 14,237 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to abo
- MarketBeat · Jul 11, 2:02 PM EDTVera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch3 Biotech Firms With Major Potential Catalysts in the Coming MonthsVera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression. The
- RTTNews · Jul 10, 12:10 PM EDTWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) – This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical sectors.
- RTTNews · Jul 8, 1:03 AM EDTVera Therapeutics Wins FDA Accelerated Approval For TRUTAKNA In Primary IgA Nephropathy(RTTNews) – Vera Therapeutics, (VERA), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted TRUTAKNA (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary IgA nephropathy or IgAN at risk for dise
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Vera Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.